Quanterix Q4 revenue $43.9M (+25% YoY); guides 2026 rev $169-174M, cash flow breakeven H2

Quanterix Corp

Q4 revenue $43.9M vs $35.2M prior year (+25%); full-year revenue $138.9M (+1% YoY).
GAAP gross margin 45.7% (Q4) and 46.8% (FY); adjusted gross margin 50.0% (Q4) and 47.3% (FY).
Adjusted EBITDA loss of $7.9M in Q4 and $44.9M for FY; cash balance $121.6M.
Initial 2026 guidance: revenue $169-174M, adjusted gross margin 49-53%, cash ~$100M year-end.
Filed 510(k) for Alzheimer's blood test; CMS set reimbursement rate of $897 for LucentAD Complete.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.